NIH × Myelodysplastic Syndromes × Clear all
NCT06904066 2026-04-16

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
NCT00588991 2025-04-02

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
NCT01168219 2022-08-04

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
68 enrolled 11 charts
NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

National Cancer Institute (NCI)

Phase 1 Completed
71 enrolled
NCT01866839 2020-07-21

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
41 enrolled 21 charts
NCT00001637 2019-12-17

Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
28 enrolled
NCT00001873 2018-09-26

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled